ANXA2 and breast cancer: Based on molecular subtypes of breast cancer specimens, strong staining of AnxA2 was predominantly observed with only triple-negative subtypes of breast cancer specimens (54.54%, n = 18) compared with other breast cancer subtypes (p < 0.0001; Figure 1B).